Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 5/20 | 0.36 |
| ▸ | CA1 | P00915 | 5/20 | 0.36 |
| ▸ | CA2 | P00918 | 5/20 | 0.36 |
| ▸ | CA9 | Q16790 | 5/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 3/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5625680 | 0.81 | PPARA (0.38) | L3MBTL1GAAPPARAHDAC1 | |
| SCHEMBL29633164 | 0.79 | MAOB (0.50) | — | |
| SCHEMBL3365028 | 0.78 | L3MBTL1 (0.43) | L3MBTL1CA12CA1CA2CA9 | |
| SCHEMBL3367105 | 0.77 | GAA (0.44) | L3MBTL1CA12CA1CA2CA9 | |
| SCHEMBL3368971 | 0.77 | GAA (0.44) | L3MBTL1CA12CA1CA2CA9 | |
| SCHEMBL29633179 | 0.77 | MIF (0.40) | CA12CA1CA2CA9 | |
| SCHEMBL14101203 | 0.74 | SMN1; SMN2 (0.44) | PDK2 | |
| SCHEMBL11032267 | 0.72 | GAA (0.54) | L3MBTL1CA12CA1CA2CA9 | |
| SCHEMBL16808252 | 0.71 | CA12 (0.44) | L3MBTL1CA12CA1CA2CA9 | |
| SCHEMBL25960280 | 0.69 | PAX8 (0.43) | L3MBTL1CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388542-A1 | ANALOGUES OF PENTAMIDINE AND USES THEREFOR | AURANSA INC. (US) | 2025-12-25 | — | — | US | disclosed |
| US-20220144776-A1 | ANALOGUES OF PENTAMIDINE AND USES THEREFOR | AURANSA INC. | 2022-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388542-A1 | ANALOGUES OF PENTAMIDINE AND USES THEREFOR | MALT1, SLC38A7, SLC7A1 | L3MBTL1 1640/4885CA12 3231/4885CA1 3742/4885 |
| US-20220144776-A1 | ANALOGUES OF PENTAMIDINE AND USES THEREFOR | DPYD, TYMP, GOT1 | L3MBTL1 2307/4885CA12 4721/4885CA1 4854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.